An old drug for a new application: Potential benefits of sildenafil in wound healing

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 15, Issue 4, 2012, Pages 483-498

  Farsaei, Shadi ^a   Khalili, Hossein ^a   Karimzadeh, Iman ^a   Dashti Khavidaki, Simin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; FIBRIN GLUE; SILDENAFIL; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; COLITIS; COLON ANASTOMOSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; GRAFT NECROSIS; HUMAN; MICROCIRCULATION; NONHUMAN; OUTCOME ASSESSMENT; RAT; RAYNAUD PHENOMENON; REVIEW; SCLERODERMA; SKIN FLAP SURVIVAL; SKIN ULCER; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TISSUE REPAIR; WOUND HEALING;

EID: 84865814708     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3tc7v     Document Type: Review

References (98)

1. McDermott-Scales L, Cowman S, Gethin G. Prevalence of wounds in a community care setting in Ireland. Journal of wound care, 2009;18(10):405-417.
2. Bours GJ HR, Abu-Saad HH, Grol RT. Prevalence, prevention, and treatment of pressure ulcers: descriptive study in 89 institutions in the Netherlands. Research in nursing & health, 2002;25(2):99-110.
3. Tas A, Atasoy N, Ozbek H, Aslan L, Yuksel H, Ceylan E, et al. The effects of sildenafil citrate (Viagra) in the early phase of healing process in open wounds in dogs. Acta Vet Brno, 2003;72:273-277.
4. Derici H KE, Unalp HR, Diniz G, Bozdag AD, Tansug T, Ortac R, Erbil Y. Effect of sildenafil on wound healing: an experimental study. Langenbecks Arch Surg, 2009:1-6.
5. Soneja A, Drews M, Malinski T. Role of nitric oxide, nitroxidative and oxidative stress in wound healing. Pharmacol Rep, 2005;57:108-119.
6. Martin P. Wound healing--aiming for perfect skin regeneration. Science, 1997;276(5309):75-81.
7. Ziche M, Morbidelli L. Nitric oxide and angiogenesis. J Neurooncol, 2000;50(1):139-148.
8. Chung AW RA, Alonso-Escolano D, Jurasz P, Stewart MW, Malinski T, Radomski MW. Plateletleukocyte aggregation induced by PAR agonists: regulation by nitric oxide and matrix metalloproteinases. Br J pharmacol 2004;143(7):845-55.
9. Cooke JP, Losordo DW. Nitric oxide and angiogenesis. Circulation, 2002;105(18):2133-2135.
10. Schwentker A, Vodovotz Y, Weller R, Billiar TR. Nitric oxide and wound repair: role of cytokines? Nitric Oxide, 2002;7(1):1-10.
11. Stallmeyer B KH, Kolb N, Pfeilschifter J, Frank S. The function of nitric oxide in wound repair: inhibition of inducible nitric oxide-synthase severely impairs wound reepithelialization. J Invest Dermatol, 1999;113(6):1090-1098.
12. Nakamura H, Herzenberg LA, Bai J, Araya S, Kondo N, Nishinaka Y, et al. Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis. Proc Natl Acad Sci U S A, 2001;98(26):15143-15148.
13. Furchgott RF. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide. JAMA, JAm Med Assoc, 1996;276(14):1186-1188.
14. Weller R, Schwentker A, Billiar TR, Vodovotz Y. Autologous nitric oxide protects mouse and human keratinocytes from ultraviolet B radiation-induced apoptosis. Am J Physiol cell Physiol, 2003;284(5):C1140-C1148.
15. Krischel V B-GD, Suschek C, Kröncke KD, Ruzicka T, Kolb-Bachofen V. Biphasic effect of exogenous nitric oxide on proliferation and differentiation in skin derived keratinocytes but not fibroblasts. J Invest Dermatol, 1998;111(2):286-291.
16. Stamler JS, Jia L, Eu JP, McMahon TJ, Demchenko IT, Bonaventura J, et al. Blood flow regulation by Snitrosohemoglobin in the physiological oxygen gradient. Science, 1997;276(5321):2034-2037.
17. Weller R, Ormerod AD, Hobson RP, Benjamin NJ. A randomized trial of acidified nitrite cream in the treatment of tinea pedis. J Am Acad Dermatol, 1998;38(4):559-563.
18. Weller R. Nitric oxide donors and the skin: useful therapeutic agents? Clin Sci (Lond), 2003;105(5):533-536.
19. Tucker A, Pearson R, Cooke E, Benjamin N. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial. The Lancet, 1999;354(9191):1670-1675.
20. Anderson M, Moore T, Hollis S, Jayson M, King T, Herrick A. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology, 2002;41(3):324-328.
21. Yamasaki K, Edington H, McClosky C, Tzeng E, Lizonova A, Kovesdi I, et al. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest, 1998;101(5):967-971.
22. Lee PC, Salyapongse AN, Bragdon GA, Shears LL, Watkins SC, Edington HDJ, et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol cell Physiol, 1999;277(4):H1600-H1608.
23. Schaffer MR, Tantry U, Efron PA, Ahrendt GM, Thornton FJ, Barbul A. Diabetes-impaired healing and reduced wound nitric oxide synthesis: a possible pathophysiologic correlation. Surgery, 1997;121(5):513-519.
24. Stallmeyer B, Anhold M, Wetzler C, Kahlina K, Pfeilschifter J, Frank S. Regulation of eNOS in normal and diabetes-impaired skin repair: implications for tissue regeneration. Nitric Oxide, 2002;6(2):168-177.
25. Witte M, Kiyama T, Barbul A. Nitric oxide enhances experimental wound healing in diabetes. Br J Surg, 2002;89(12):1594-1601.
26. Witte MB, Thornton FJ, Tantry U, Barbul A. LArginine supplementation enhances diabetic wound healing: Involvement of the nitric oxide synthase and arginase pathways. Metabol, Clin Exp, 2002;51(10):1269-1273.
27. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol, 1999;83(5):21-28.
28. Boolell M, Gepi-Attee S, Gingell J, Allen M. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol, 1996;78(2):257-261.
29. Jackson G, Gillies H, Osterloh I. Past, present, and future: a 7-year update of Viagra (sildenafil citrate). Int J Clin Pract, 2005;59(6):680-691.
30. Basson R, McInnes R, Smith MD, Hodgson G, Koppiker N. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder. J Womens Health Gend Based Med, 2002;11(4):367-377.
31. Laan E, Van Lunsen RHW, Everaerd W, Riley A, Scott E, Boolell M. The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women. J Womens Health Gend Based Med, 2002;11(4):357-365.
32. Caruso S, Intelisano G, Lupo L, Agnello C. Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. Br J Obstet Gynaecol, 2001;108(6):623-628.
33. Zhang R, Wang Y, Zhang L, Zhang Z, Tsang W, Lu M, et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke, 2002;33(11):2675-2680.
34. Zhang R, Wang L, Zhang L, Chen J, Zhu Z, Zhang Z, et al. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP after stroke in the rat. Circulation research, 2003;92(3):308-313.
35. Das S, Maulik N, Das D, Kadowitz P, Bivalacqua T. Cardioprotection with sildenafil, a selective inhibitor of cyclic 3', 5'-monophosphate-specific phosphodiesterase 5. Drugs Exp Clin Res, 2002;28(6):213-219.
36. Salloum F, Yin C, Xi L, Kukreja RC. Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res, 2003;92(6):595-597.
37. Sastry B, Narasimhan C, Reddy N, Anand B, Prakash G, Raghava Raju P, et al. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J, 2002;54(4):410-414.
38. Sastry B, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension:: A randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol, 2004;43(7):1149-1153.
39. Chen YJ, Traverse JH, Hou M, Li Y, Du R, Bache RJ. Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure. Am J Physiol Heart Circ Physiol, 2003;284(5):H1513-H1520.
40. Fischer T, Erbel R, Treese N. Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure. Drugs, 1992;44(6):928-945.
41. Ulusoy MG, Uysal A, Koaser U, Karaaslan Ã, Cuzdan SS, Ayyldz A, et al. Improved flap viability with site-specific delivery of sildenafil citrate using fibrin glue. Annals of plastic surgery, 2005;55(3):292.
42. Sarifakioglu N, Gokrem S, Ates L, Akbuga UB, Aslan G. The influence of sildenafil on random skin flap survival in rats: an experimental study. Br J Plast Surg, 2004;57(8):769-772.
43. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell, 2003;112(1):77-86.
44. Gore J, Silver R. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis, 2005;64(9):1387.
45. Ambach A, Seo W, Bonnekoh B, Gollnick H. Lowdose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil. JDDG, 2009;7(10):888-891.
46. Chung L. Therapeutic options for digital ulcers in patients with systemic sclerosis. J Dtsch Dermatol Ges, 2007;5(6):460-465.
47. Moinzadeh P, Hunzelmann N, Krieg T. Combination therapy with an endothelin-1 receptor antagonist (bosentan) and a phosphodiesterase V inhibitor (sildenafil) for the management of severe digital ulcerations in systemic sclerosis. J Am Acad Dermatol, 2011;65(3):102-104.
48. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl, 2008;14(3):287-291.
49. Catapano-Minotti G, Corsonello A, Guadalupi G, Spani R, Antonelli-Incalzi R. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach. Intern Med, 2008;47(6):511.
50. Ayyildiz A UA, Koçer U, Karaaslan O, Huri E, Germiyanoglu C, Caydere M. Effect of sildenafil citrate on viability of flaps: an experimental study in rats. Scand J Plast Reconstr Surg Hand Surg, 2005;39(4):204-208.
51. Hart K BD, Hodam J, Lesoon-Wood L, Parham M, Keith K, Vazquez R, Ager E, Pizarro J. Short-and long-term effects of sildenafil on skin flap survival in rats. Laryngoscope, 2006;116(4):522-528.
52. Konstantinos G, Petros P. Phosphodiesterase-5 inhibitors: future perspectives. Current pharmaceutical design, 2009;15(30):3540-3551.
53. Tsai JW, Ayubi FS, Hart KL, Baur DA, Parham MA, Moon JK, et al. Evaluation of the effect of sildenafil and vascular endothelium growth factor combination treatment on skin flap survival in rats. Aesthetic Plast Surg, 2008;32(4):624-631.
54. Ayyildiz A, Akgul K, Nuhoglu B, Huri E, Caydere M, Ustun H, et al. An Experimental study: Does topically applied sildenafil citrate (Sildegra®) have an effect on the preservation of the viability of the graft in full-thickness tubed free skin grafts?. Turk J Med Sci, 2006;36(6):343-348.
55. Irkorucu O TO, Cakmak GK, Karakaya K, Emre AU, Ucan BH, Bahadir B, Acikgoz S, Ankarali H, Ugurbas E, Comert M. The effect of sildenafil on an animal model for ischemic colitis. Dig Dis Sci, 2008;53(6):1618-1623.
56. Batukan C, Ozgun MT, Basbug M, Muderris II. Sildenafil reduces postoperative adhesion formation in a rat uterine horn model. Eur J Obstet Gynecol Reprod Biol, 2007;135(2):183-187.
57. Irkorucu O, Ucan BH, Cakmak GK, Emre AU, Tascilar O, Ofluoglu E, et al. Does sildenafil reverse the adverse effects of ischemia on ischemic colon anastomosis: yes, 'no'. Int J Surg, 2009;7(1):39-43.
58. Uzun H KD, Nuri MK, Ersoy EY, Ozçevik S, Yavuz N. The effects of sildenafil citrate on ischemic colonic anastomotic healing in rats: its relationship between nitric oxide and oxidative stress. World J Surg, 2008;32(9):2107-2113.
59. Barral SM, Araujo ID, Vidigal PVT, Mayrink CAC, Araujo AD, Costa PR. Effects of sildenafil on the viability of random skin flaps. Acta Cir Bras, 2011;26(4):314-319.
60. Ayten R CZ, Girgin M, Ozercan I, Ustundag B, Aygen E. The effects of intraperitoneal sildenafil administration on healing of left colonic anastomoses and intra-abdominal adhesion formation in the presence of intra-abdominal infection. Dis Colon Rectum, 2008;51(12):1837-1841.
61. Jamshidzadeh A, Azarpira N. The Effects of Topical Sildenafil on Wound Healing in Rat. Iranian Journal of Pharmaceutical Sciences, 2010;7(1):43-48.
62. Colglazier CL, Sutej PG, O'Rourke KS. Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil. The Journal of rheumatology, 2005;32(12):2440-2442.
63. Ng WK RY, Brock GB, O'Gorman DB, Siang Gan B. Phosphodiesterase inhibitors in vascular ischemia: A case report and review of their use in ischemic conditions. Can J Plast Surg, 2010;18(1):e5-e9.
64. Gertner E. Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome. Lupus, 2003;12(2):133-135.
65. Wollina U BM, Heinig B, Petrov I, Unger E, Kyriopoulou E, Koch A, Köstler E, Schönlebe J, Haroske G, Doede T, Pramatarov K. Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma. Int J Low Extrem Wounds, 2007;6(4):291-298.
66. Brueckner CS, Becker MO, Kroencke T, Huscher D, Scherer HU, Worm M, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis, 2010;69(8):1475-1478.
67. Rossa AD, Doveri M, D'Ascanio A, Tavoni A, Consensi A, Neri R, et al. Oral sildenafil in skin ulcers secondary to systemic sclerosis. Scand J Rheumatol, 2011;40(4):323-325.
68. Vural E, Key JM. Complications, salvage, and enhancement of local flaps in facial reconstruction. Otolaryngol Clin North Am, 2001;34(4):739-751.
69. Slate RK, Ryan M, Bongard FS. Dependence of tissue oxygen on oxygen delivery. J Surg Res, 1996;61(1):201-205.
70. Tüz M EE, Doǧru H, Delibaş N, Tunç B, Uygur K. The effect of replacement fluids and normovolaemic haemodilution on the survival of dorsal skin flaps in rats. Clin Otolaryngol Allied Sci, 2004;29(1):80-83.
71. Ergün H CM, Apaydin I, Erçöçen AR, Tulunay FC. The effect of dipyrone on survival of skin flaps. Scand J Plast Reconstr Surg Hand Surg, 2001;35(1):19-22.
72. Davis RE, Wachholz JH, Jassir D, Perlyn CA, Agrama MH. Comparison of topical anti-ischemic agents in the salvage of failing random-pattern skin flaps in rats. Facial Plast Surg, 1999;1(1):27-32.
73. Kerrigan CL, Daniel RK. Pharmacologic treatment of the failing skin flap. Plast Reconstr Surg, 1982;70(5):541-549.
74. Akgün A KS, Uraldi C, Tekin O, Karip B, Tug T, Ongören AU. Early effects of fibrin sealant on colonic anastomosis in rats: an experimental and case-control study. Tech Coloproctol, 2006;10(3):208-214.
75. Nasir Khan MU, Abir F, Longo W, Kozol R. Anastomotic disruption after large bowel resection. World J Gastroenterol, 2006;12(16):2497-2504.
76. Angel MF, Ramasastry SS, Swartz WM, Narayanan K, Kuhns DB, Basford R, et al. The critical relationship between free radicals and degrees of ischemia: evidence for tissue intolerance of marginal perfusion. Plast Reconstr Surg, 1988;81(2):233-239.
77. Chiu CJ, McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states: I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg, 1970;101(4):478-483.
78. Nair SK, Bhat IK, Aurora AL. Role of proteolytic enzyme in the prevention of postoperative intraperitoneal adhesions. Arch Surg, 1974;108(6):849-853.
79. Leach RE, Burns JW, Dawe EJ, Smith Barbour MD, Diamond MP. Reduction of postsurgical adhesion formation in the rabbit uterine horn model with use of hyaluronate/carboxymethylcellulose gel. Fertil Steril, 1998;69(3):415-418.
80. Knightly J, Agostino D, Cliffton E. The effect of fibrinolysin and heparin on the formation of peritoneal adhesions. Surgery, 1962;52:250-258.
81. Woessner J. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys, 1961;93(2):440-447.
82. Ehrlich HP, Tarver H, Hunt TK. Effects of vitamin A and glucocorticoids upon inflammation and collagen synthesis. Ann Surg, 1973;177(2):222-227.
83. Li H, Fu X, Zhang L, Huang Q, Wu Z, Sun T. Research of PDGF-BB gel on the wound healing of diabetic rats and its pharmacodynamics. J Surg Res, 2008;145(1):41-48.
84. Qiu Z, Kwon A, Kamiyama Y. Effects of plasma fibronectin on the healing of full-thickness skin wounds in streptozotocin-induced diabetic rats. J Surg Res, 2007;138(1):64-70.
85. Gulcelik MA, Dinc S, Dinc M, Yenidogan E, Ustun H, Renda N, et al. Local granulocyte-macrophage colony-stimulating factor improves incisional wound healing in adriamycin-treated rats. Surg Today, 2006;36(1):47-51.
86. Abramov Y, Golden B, Sullivan M, Botros SM, Miller JJR, Alshahrour A, et al. Histologic characterization of vaginal vs. abdominal surgical wound healing in a rabbit model. Wound Repair Regen, 2007;15(1):80-86.
87. Gibson GE, Daniel Su W, Pittelkow MR. Antiphospholipid syndrome and the skin. J Am Acad Dermatol, 1997;36(6):970-982.
88. Gertner E, Lie J. Systemic therapy with fibrinolytic agents and heparin for recalcitrant nonhealing cutaneous ulcer in the antiphospholipid syndrome. J Rheumatol, 1994;21(11):2159.
89. Furst DE. Rational therapy in the treatment of systemic sclerosis. Curr Opin Rheumatol, 2000;12(6):540-544.
90. Sunderkötter C, Riemekasten G. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatology, 2006;45(suppl 3):iii33-35.
91. Abraham D, Distler O. How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther, 2007;9(2):2.
92. Korn J, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum, 2004;50(12):3985-3993.
93. Kawald A BG, Huscher D, Sunderkötter C, Riemekasten G. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol, 2008;35(9):1830-1837.
94. Matucci Cerinic M, Kahaleh M. Beauty and the Beast. The nitric oxide paradox in systemic sclerosis. Rheumatology, 2002;41(8):843-847.
95. Freedman RR, Girgis R, Mayes MD. Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma. The Lancet, 1999;354(9180):739.
96. Friedrichson E, Rehberger P, Fuhrmann J, Walz F, Meurer M, Pfeiffer C. [Fast and efficient healing of scleroderma-associated acral ulcers with sildenafil]. Hautarzt, 2008;59(3):230-232.
97. Wollina U, Heinig B, Uhlemann C. Transdermal CO2 application in chronic wounds. Int J Lower Extremity Wounds, 2004;3(2):103-106.
98. McLafferty RB, Edwards JM, Taylor LM, Porter JM. Diagnosis and long-term clinical outcome in patients diagnosed with hand ischemia. J Vasc Surg, 1995;22(4):361-369.